DYN (Dyne Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

Dyne Therapeutics, Inc. Common Stock (DYN) is a publicly traded Healthcare sector company. As of May 20, 2026, DYN trades at $16.89 with a market cap of $2.73B and a P/E ratio of -4.65. DYN moved +3.20% today. Year to date, DYN is -13.95%; over the trailing twelve months it is +36.54%. Its 52-week range spans $6.36 to $36.09. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces DYN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate DYN?

11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $35.31.

DYN Key Metrics

Key financial metrics for DYN
MetricValue
Price$16.89
Market Cap$2.73B
P/E Ratio-4.65
EPS$-3.47
Dividend Yield0.00%
52-Week High$36.09
52-Week Low$6.36
Volume232.40K
Avg Volume0
Revenue (TTM)$0
Net Income$-446.21M
Gross Margin0.00%

DYN Analyst Consensus

11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.

Latest DYN News

Recent DYN Insider Trades

  • Friedl-Naderer Johanna sold 228 (~$4.19K) on May 13, 2026.
  • Kerr Douglas sold 1.56K (~$28.72K) on May 13, 2026.
  • Lucera Erick sold 1.45K (~$26.59K) on May 13, 2026.

Common questions about DYN

What do analysts rate DYN?
11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $35.31.
Does Rallies show DYN price targets?
Yes. Rallies tracks DYN analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is DYN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DYN. It does not provide personalized investment advice.
DYN

DYN